📈 Fundamentals remain intact💰 For 4Q FY26, SUN reported a recurring EPS of LKR 0.25 (+288% YoY) stemming from PATMI of LKR 496mn. Topline growth was supported by growth across all segments while EBIT margins contracted owing to NMRA pricing formula updates reducing MRPs of pharmaceuticals and price reductions in government orders for pharma manufacturing impacting the healthcare margins. 📘 BRS Outlook: Near term Healthcare margins to be compressed. Integration of JAPC to strengthen Consumer topline. Agribusiness to remain strong with strong palm oil pricing and improved yields.